A pan-cancer screen identifies drug combination benefit in cancer cell lines at the individual and population level.

Next, we investigated for shared combinations ( N = 7) whether we could detect an overall trend between the fraction of synergistic cell lines and the hazard ratio of a combination against the placebo.

also in 4,871 other papers

Specifically, when comparing the combination effect in the PDXs against the effect of the single treatments (BYL719 and binimetinib) and the untreated cohort, the combination showed highly significant hazard ratios of 0.28, 0.18, and 0.02 with associated p values of 3.9e−5, 1.7e−6, and 4.8e−5, respectively ( Figure 5 C).

also in 132,142 other papers